Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

TScan Therapeutics reports IND clearances for two TCR-T candidates

TScan Therapeutics (NASDAQ:TCRX), a clinical-stage biopharmaceutical company developing T cell receptor (TCR)-engineered T cell therapies for the treatment of cancer, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update focused on progress across its allogeneic TCR-T platform.

Leia mais: TScan Therapeutics reports IND clearances for two TCR-T candidates
Grafa
Health

Ocugen reports Q4 net loss of $17.7M with FY loss reaching $67.8M

Ocugen (NASDAQ:OCGN), a Malvern, Pennsylvania-based clinical-stage biotechnology company developing modifier gene therapies for ophthalmic and other diseases, on Wednesday reported financial results for the fourth quarter and full year ended December 31, 2025, alongside a business update highlighting progress across its three lead modifier gene therapy programs.

Leia mais: Ocugen reports Q4 net loss of $17.7M with FY loss reaching $67.8M
Grafa
Health

Cellectar Biosciences advances lead radiotherapy toward regulatory submission

Cellectar Biosciences (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company specializing in radioconjugates, reported a significantly reduced net loss for 2025 as it transitioned its lead program, iopofosine I-131, into the final regulatory stages.

Leia mais: Cellectar Biosciences advances lead radiotherapy toward regulatory submission